You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Angiogenesis Inhibitors

Showing 1 - 25 of 5,124
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced

Completed
  • NSCLC
  • Immune checkpoint inhibitors plus angiogenesis inhibitors
  • Immune checkpoint inhibitors without angiogenesis inhibitors
  • Suzhou, Jiangsu, China
    The Affiliated Suzhou Hospital of Nanjing Medical University
Jan 17, 2023

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma Trial in Beijing (Anlotinib Hydrochloride

Not yet recruiting
  • Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
  • Anlotinib Hydrochloride Capsule and Penpulimab
  • Beijing, Beijing, China
    YansongLin
Sep 25, 2023

Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)

Not yet recruiting
  • Carcinoma
  • +7 more
  • (no location specified)
Nov 12, 2023

Retinal Pigment Epithelium Detachment in Neovascular Age-related

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • Anti-vascular endothelial growth factor therapy
  • Krasnodar, Russian Federation
    The S.N. Fyodorov Eye Microsurgery State Institution
Jan 12, 2022

NSCLC, Angiogenesis, Immunotherapy Trial in Qingdao (Anlotinib in combination with Immune checkpoint inhibitors)

Completed
  • NSCLC
  • +2 more
  • Anlotinib in combination with Immune checkpoint inhibitors
  • Qingdao, China
    The Affiliated Hospital of Qingdao University
Dec 10, 2020

Solid Tumor, Adult, Hepatocellular Carcinoma Trial in Guangzhou (Combination of three inhibitors Trametinib, Everolimus and

Recruiting
  • Solid Tumor, Adult
  • Hepatocellular Carcinoma
  • Combination of three inhibitors Trametinib, Everolimus and Lenvatinib
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Apr 7, 2021

Tamoxifen and Aromatase Inhibitors on Platelet Proteins

Completed
  • Breast Cancer
    • Burlington, Vermont
      University of Vermont
    Sep 15, 2020

    Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Tumors, Tumors by Site Trial in Nanjing (Anlotinib, Olaparib)

    Recruiting
    • Ovarian Cancer
    • +18 more
    • Nanjing, Jangsu, China
      JiangSu Cancer Hospital
    Oct 29, 2020

    Ovarian Tumors, Fallopian Tube Tumors, Endocrine Gland Tumors Trial in Nanjing (Niraparib, Bevacizumab)

    Unknown status
    • Ovarian Neoplasms
    • +23 more
    • Nanjing, Jiangsu, China
      JiangSu Cancer Hospital
    Nov 8, 2020

    Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced

    Recruiting
    • Esophageal Neoplasms
    • an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
    • Zhengzhou, Henan, China
      The First Affiliated Hospital of Zhengzhou University
    Apr 21, 2022

    Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
    • TACE
    • Nanjing, China
    • +1 more
    Dec 28, 2022

    Hepatocellular Carcinoma Trial in Hangzhou (PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • PVE+cTACE+Camrelizumab+Apatinib
    • cTACE+Atirizumab+Bevacizumab
    • Hangzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Feb 26, 2023

    Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
    • TACE
    • Nanjing, China
    • +1 more
    Dec 28, 2022

    Port Wine Stain Trial (Topical Antiangiogenic, Pulsed Dye Laser)

    Withdrawn
    • Port Wine Stain
    • Topical Antiangiogenic
    • Pulsed Dye Laser
    • (no location specified)
    Oct 28, 2022

    Therapeutic Combination in Advanced or Metastatic Kidney Cancer

    Not yet recruiting
    • Renal Cell Carcinoma
    • +2 more
    • Blood collection
    • Tumour samples
    • Paris, France
    • +1 more
    Mar 9, 2022

    Breast Cancer Trial in Guangzhou (Anlotinib)

    Not yet recruiting
    • Breast Cancer
    • Guangzhou, Guangdong, China
      Guangdong Women and Children Hospital
    Jul 26, 2021

    Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

    Not yet recruiting
    • Ovarian Cancer
    • +4 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Cetntre
    Sep 25, 2023

    Upper Aerodigestive Malignancies

    Recruiting
    • Head and Neck Cancer
    • +2 more
    • Collection of biological specimens
    • Baltimore, Maryland
      Johns Hopkins University
    Aug 9, 2023

    Solid Tumor, Adult, Solid Tumor, Gastric Cancer Trial in Seongnam, Seoul (PB101)

    Recruiting
    • Solid Tumor, Adult
    • +5 more
    • Seongnam, Korea, Republic of
    • +2 more
    Oct 11, 2023

    Rheumatoid Arthritis Trial ("apigenin" and "glycyrrhizin", "glycyrrhizin" and "boswellic acid", "")

    Not yet recruiting
    • Rheumatoid Arthritis
    • "apigenin" and "glycyrrhizin"
    • +2 more
    • (no location specified)
    Mar 27, 2023

    NSCLC Trial in Tianjin (Tislelizumab, Pemetrexed, Bevacizumab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Jul 11, 2022

    Screening of Preeclampsia and Intrauterine Growth Restriction

    Completed
    • Preeclampsia
    • Intrauterine Growth Restriction
    • Ultrasound study of the placenta
    • Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test
    • Barcelona, Spain
      Hospital de la Santa Creu i Sant Pau
    Mar 8, 2022

    AMD, nAMD, Wet Age-related Macular Degeneration Trial in United States (RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (EYLEA®))

    Recruiting
    • AMD
    • +5 more
    • RGX-314 Dose 1
    • +2 more
    • Encino, California
    • +16 more
    Jun 2, 2022

    MDS Trial in Beijing (Lenalidomide, Azacitidine)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Beijing, China
      Peking union medical college hospital
    Aug 16, 2023

    Renal Cell Carcinoma Trial in Leiden (Light breakfast)

    Not yet recruiting
    • Renal Cell Carcinoma
    • Light breakfast
    • Leiden, Zuid-Holland, Netherlands
      Leids Universitair Medisch Centrum
    Jul 4, 2022